Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Jul 26, 2016
LA JOLLA, Calif., July 26, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will release second quarter financial results on Tuesday, August 2, 2016 after the market closes. Regulus will host a c...
Jul 5, 2016
LA JOLLA, Calif., July 5, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Joseph "Jay" Hagan, Chief Operating Officer of Regulus, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthca...
Jun 27, 2016
LA JOLLA, Calif., June 27, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) for RG-101 for the...
Jun 20, 2016
LA JOLLA, Calif., June 20, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it has entered into a $30 million loan and security agreement with Oxford Finance LLC.  Proceeds from the loan will be used to provid...
Jun 7, 2016
LA JOLLA, Calif., June 7, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced  top-line results from the primary endpoint analysis of one of the company's ongoing Phase II studies of RG-101 for the treatment of He...
Jun 3, 2016
LA JOLLA, Calif., June 3, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the Jefferies 2016 Healthca...
Jun 2, 2016
LA JOLLA, Calif., June 2, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced Hugh Rosen, M.D., Ph.D. was elected to the Company's board of directors at its Annual Meeting of Stockholders held earlier today...
Jun 1, 2016
LA JOLLA, Calif., June 1, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded its clinical trial collaboration agreement with GSK (NYSE: GSK) for the development of RG-101, Regulus' who...
May 23, 2016
LA JOLLA, Calif., May 23, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Allison Wey has been appointed Vice President, Investor Relations and Corporate Communications.  Ms. Wey brings over 25 years of ...
May 20, 2016
LA JOLLA, Calif., May 20, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new data on RG-012, the company's anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney ...
Page: FirstPrevious
4
... NextLast
= add release to Briefcase